Eledon Pharmaceuticals annual meeting elects directors and ratifies auditor

Eledon Pharmaceuticals, Inc.

Stockholders elected Keith A. Katkin (7,330,714 for, 765,231 withhold) and John S. McBride (7,287,222 for, 808,723 withhold) as Class II directors for term ending 2025.
Ratified KMJ Korbin & Company LLP as independent auditor for FY2022 with 10,173,336 for, 10,380 against, 3,433 abstain.
All proposals passed at the June 21, 2022 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.